Filtered By:
Cancer: Lung Cancer

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 15396 results found since Jan 2013.

Impact of the new EGF receptor and ALK testing guideline on personalized lung cancer medicine
Personalized Medicine , July 2013, Vol. 10, No. 5, Pages 415-417.
Source: Future Medicine: Personalized Medicine - July 4, 2013 Category: Genetics & Stem Cells Tags: article Source Type: research

Recent advances in personalized lung cancer medicine
Personalized Medicine May 2014, Vol. 11, No. 3, Pages 309-321.
Source: Future Medicine: Personalized Medicine - June 17, 2014 Category: Genetics & Stem Cells Tags: article Source Type: research

Highlights from the latest articles in lung cancer personalized medicine
Personalized Medicine June 2014, Vol. 11, No. 4, Pages 377-379.
Source: Future Medicine: Personalized Medicine - August 18, 2014 Category: Genetics & Stem Cells Tags: article Source Type: research

Chemotherapy in conjunction with traditional Chinese medicine for survival of elderly patients with advanced non-small-cell lung cancer: protocol for a randomized double-blind controlled trial
DISCUSSION Results from this study may provide evidence on the effectiveness, and parameters for the usage of single-agent chemotherapy combined with or without TCM on PFS of elderly patients with NSCLC. TRIAL REGISTRATION ClinicalTrials.gov. (Identifier: NCT01780181).
Source: Journal of Integrative Medicine - November 3, 2014 Category: Complementary Medicine Source Type: research

Joint Statement of the Ad-hoc Committee of the Korean Society for Preventive Medicine and the Korean Society of Epidemiology on Tobacco Lawsuits on the Causal Link Between Tobacco Smoking and Lung Cancer.
Authors: Ad-hoc Committee of the Korean Society for Preventive Medicine and the Korean Society of Epidemiology on Tobacco Lawsuits PMID: 26081649 [PubMed - in process]
Source: Journal of Preventive Medicine and Public Health - June 19, 2015 Category: Global & Universal Tags: J Prev Med Public Health Source Type: research

PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?
Abstract The success of immune checkpoint inhibitor therapy in lung cancer, both in squamous and nonsquamous non-small cell carcinoma, has led to US Food and Drug Administration approval for 2 medications that have as part of their prescribing information an associated immunohistochemistry-based companion or complementary diagnostic test for programmed death ligand 1 (PD-L1). The intense interest in drug development in this area has resulted in additional agents with associated diagnostics looming on the horizon in 2016. In the era of precision medicine, the paradigm of paired molecular target and molecular test, ...
Source: Archives of Pathology and Laboratory Medicine - January 12, 2016 Category: Laboratory Medicine Authors: Borczuk AC, Allen TC Tags: Arch Pathol Lab Med Source Type: research

Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients.
CONCLUSIONS: CHM is well tolerated and may improve the QOL of advanced NSCLC patients. CHM is worth studying in future investigations. PMID: 26860807 [PubMed - in process]
Source: Complementary Therapies in Medicine - February 1, 2016 Category: Complementary Medicine Authors: Han Y, Wang H, Xu W, Cao B, Han L, Jia L, Xu Y, Zhang Q, Wang X, Zhang G, Yu M, Yang G Tags: Complement Ther Med Source Type: research

Traditional Chinese Medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: A randomized controlled trial.
CONCLUSIONS: TCM maintenance treatment had similar effects on TTP and OS compared with maintenance chemotherapy, but it improved patients' QOL and had higher 1-year survival rate. TCM Maintenance treatment is a promising option for advanced NSCLC patients without progression following first-line chemotherapy. PMID: 26860802 [PubMed - in process]
Source: Complementary Therapies in Medicine - February 1, 2016 Category: Complementary Medicine Authors: Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ Tags: Complement Ther Med Source Type: research

Use of complementary and alternative medicine by lung cancer patients in Korea: A qualitative study
Conclusion As CAM gave a chance for patients to concentrate on ‘self’ and regain the will to continue with treatment, CAM potentially improves lung cancer patients’ QoL. Effective application of CAM during cancer treatment should be investigated.
Source: European Journal of Integrative Medicine - February 18, 2016 Category: Complementary Medicine Source Type: research

Traditional herbal medicine as an adjuvant treatment for non-small-cell lung cancer: A systematic review and meta-analysis
Conclusions The pooled results of this systematic review and meta-analysis suggest that THM significantly improved the QoL for patients with NSCLC.
Source: European Journal of Integrative Medicine - February 18, 2016 Category: Complementary Medicine Source Type: research

Chinese Herbal Medicine Fuzheng Kang-Ai Decoction Inhibited Lung Cancer Cell Growth through AMPKα-Mediated Induction and Interplay of IGFBP1 and FOXO3a.
Authors: Zheng F, Wu J, Li X, Tang Q, Yang L, Yang X, Wu W, Hann SS Abstract The aim of this study is to investigate the actions of Chinese herbal medicine, called "Fuzheng Kang-Ai" (FZKA for short) decoction, against non-small cell lung cancer (NSCLC) and its mechanisms in vitro and in vivo. We showed that the effect of FZKA decoction significantly inhibited growth of A549 and PC9 cells. Furthermore, FZKA increased phosphorylation of AMP-activated protein kinase alpha (AMPKα) and induced protein expression of insulin-like growth factor (IGF) binding protein 1 (IGFBP1) and forkhead homeobox type O3a (FOXO3a). The ...
Source: Evidence-based Complementary and Alternative Medicine - April 10, 2016 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Epigenetic Profiling of H3K4Me3 Reveals Herbal Medicine Jinfukang-Induced Epigenetic Alteration Is Involved in Anti-Lung Cancer Activity.
Authors: Lu J, Zhang X, Shen T, Ma C, Wu J, Kong H, Tian J, Shao Z, Zhao X, Xu L Abstract Traditional Chinese medicine Jinfukang (JFK) has been clinically used for treating lung cancer. To examine whether epigenetic modifications are involved in its anticancer activity, we performed a global profiling analysis of H3K4Me3, an epigenomic marker associated with active gene expression, in JFK-treated lung cancer cells. We identified 11,670 genes with significantly altered status of H3K4Me3 modification following JFK treatment (P < 0.05). Gene Ontology analysis indicates that these genes are involved in tumor-related...
Source: Evidence-based Complementary and Alternative Medicine - April 20, 2016 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Authors: Nishimura T, Nakamura H Abstract Molecular therapies targeting lung cancers with mutated epidermal growth factor receptor (EGFR) by EGFR-tyrosin kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, changed the treatment system of lung cancer. It was revealed that drug efficacy differs by race (e.g., Caucasians vs. Asians) due to oncogenic driver mutations specific to each race, exemplified by gefitinib / erlotinib. The molecular target drugs for lung cancer with anaplastic lymphoma kinase (ALK) gene translocation (the fusion gene, EML4-ALK) was approved, and those targeting lung cancers addicted ROS1, R...
Source: Advances in Experimental Medicine and Biology - October 2, 2016 Category: Research Tags: Adv Exp Med Biol Source Type: research

Recent highlights of Chinese medicine for advanced lung cancer
AbstractOwing to its unique superiority in improving quality of life and prolonging survival time among advanced lung cancer patients, Chinese medicine (CM) has, in recent years, received increased attentions worldwide. We utilized a bibliometric statistical method based on MEDLINE/GoPubMed to conduct a comprehensive analysis of the current application status of CM in lung cancer, by including annual and accumulated publications, origin distribution of countries and journals, and keywords with a higher frequency score. Then the relevant clinical trials and mechanistic studies were systematically summarized within the field...
Source: Chinese Journal of Integrative Medicine - December 26, 2016 Category: Internal Medicine Source Type: research

Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept.
Authors: Zhu YJ, Zhang HB, Liu LR, Liu YH, Zhang FL, Bai JP, Li Y, Qu YC, Qu X, Chen X, Li Y, Luo SY, Ou AH Abstract Traditional Chinese Medicine (TCM) therapies should be tailored according to the different syndrome types. In order to identify the relationship between the TCM Yin-cold (YC) or Yang-heat (YH) syndrome types and the EGFR gene status, we prospectively studied 310 NSCLC patients. TCM YH or YC was diagnosed by three TCM experts. TCM symptoms and signs were entered into a binary cluster analysis. The relationships between the EGFR gene status, YH or YC syndrome types, and classification by cluster analys...
Source: Evidence-based Complementary and Alternative Medicine - February 18, 2017 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research